192 related articles for article (PubMed ID: 26276725)
1. Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells.
Hsiao CC; Chen PH; Cheng CI; Tsai MS; Chang CY; Lu SC; Hsieh MC; Lin YC; Lee PH; Kao YH
Cancer Lett; 2015 Nov; 368(1):144-152. PubMed ID: 26276725
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro.
Hsiao CC; Kao YH; Huang SC; Chuang JH
Pediatr Blood Cancer; 2013 Feb; 60(2):248-53. PubMed ID: 22648929
[TBL] [Abstract][Full Text] [Related]
3. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells.
Xia MZ; Liang YL; Wang H; Chen X; Huang YY; Zhang ZH; Chen YH; Zhang C; Zhao M; Xu DX; Song LH
J Pineal Res; 2012 Nov; 53(4):325-34. PubMed ID: 22537289
[TBL] [Abstract][Full Text] [Related]
4. A896G and C1196T Polymorphisms Within the TLR4 Gene Abate Toll-Like Receptor 4-Mediated Signaling in HepG2 Cells.
Huang C; Zhang H; Bai R; Wang L; Lv J
DNA Cell Biol; 2017 Nov; 36(11):1029-1038. PubMed ID: 28945461
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
Zhang Y; Wang Y; Yuan J; Qin W; Liu F; Wang F; Zhang G; Yang X
Cell Biol Toxicol; 2012 Aug; 28(4):269-77. PubMed ID: 22648782
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma.
Wang L; Zhu R; Huang Z; Li H; Zhu H
Dig Dis Sci; 2013 Aug; 58(8):2223-36. PubMed ID: 23828139
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens.
Kobayashi T; Kubota M; Kinoshita Y; Arai Y; Oyama T; Yokota N; Saito K; Matsuda Y; Osawa M
Pediatr Surg Int; 2019 Dec; 35(12):1369-1378. PubMed ID: 31559456
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis B core antigen promotes invasion of hepatocellular carcinoma cell line HepG2.2.15 via Toll-like receptor 4].
Hou HR; Kang Y; Li YK; Zeng YL; Wei JF; Ding GG; Peng Z; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):908-913. PubMed ID: 29325291
[No Abstract] [Full Text] [Related]
9. Functional Toll-like receptor 4 expressed in lactotrophs mediates LPS-induced proliferation in experimental pituitary hyperplasia.
Sabatino ME; Sosa Ldel V; Petiti JP; Mukdsi JH; Mascanfroni ID; Pellizas CG; Gutiérrez S; Torres AI; De Paul AL
Exp Cell Res; 2013 Nov; 319(19):3020-34. PubMed ID: 23973924
[TBL] [Abstract][Full Text] [Related]
10. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide enhances Wnt5a expression through toll-like receptor 4, myeloid differentiating factor 88, phosphatidylinositol 3-OH kinase/AKT and nuclear factor kappa B pathways in human dental pulp stem cells.
He W; Wang Z; Zhou Z; Zhang Y; Zhu Q; Wei K; Lin Y; Cooper PR; Smith AJ; Yu Q
J Endod; 2014 Jan; 40(1):69-75. PubMed ID: 24331994
[TBL] [Abstract][Full Text] [Related]
12. CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway.
Wang Y; Tu Q; Yan W; Xiao D; Zeng Z; Ouyang Y; Huang L; Cai J; Zeng X; Chen YJ; Liu A
Biochem Biophys Res Commun; 2015 Jan; 456(1):373-9. PubMed ID: 25475726
[TBL] [Abstract][Full Text] [Related]
13. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.
Kawamoto T; Ii M; Kitazaki T; Iizawa Y; Kimura H
Eur J Pharmacol; 2008 Apr; 584(1):40-8. PubMed ID: 18299127
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression.
Zu Y; Ping W; Deng T; Zhang N; Fu X; Sun W
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27061118
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling.
Wang Y; Cai J; Zeng X; Chen Y; Yan W; Ouyang Y; Xiao D; Zeng Z; Huang L; Liu A
BMC Cancer; 2015 Oct; 15():821. PubMed ID: 26514586
[TBL] [Abstract][Full Text] [Related]
16. Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation.
Jin J; Jin J; Woodfield SE; Patel RH; Jin NG; Shi Y; Liu B; Sun W; Chen X; Yu Y; Vasudevan SA
Oncol Rep; 2019 Jan; 41(1):143-153. PubMed ID: 30320362
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
Shi Y; Wang SY; Yao M; Sai WL; Wu W; Yang JL; Cai Y; Zheng WJ; Yao DF
World J Gastroenterol; 2015 Dec; 21(45):12814-21. PubMed ID: 26668505
[TBL] [Abstract][Full Text] [Related]
18. Female sex hormones modulate Porphyromonas gingivalis lipopolysaccharide-induced Toll-like receptor signaling in primary human monocytes.
Jitprasertwong P; Charadram N; Kumphune S; Pongcharoen S; Sirisinha S
J Periodontal Res; 2016 Jun; 51(3):395-406. PubMed ID: 26364725
[TBL] [Abstract][Full Text] [Related]
19. TLR4 Promotes Breast Cancer Metastasis via Akt/GSK3β/β-Catenin Pathway upon LPS Stimulation.
Li J; Yin J; Shen W; Gao R; Liu Y; Chen Y; Li X; Liu C; Xiang R; Luo N
Anat Rec (Hoboken); 2017 Jul; 300(7):1219-1229. PubMed ID: 28296189
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes: biological significance and clinical implications in human pathology.
Panaro MA; Gagliardi N; Saponaro C; Calvello R; Mitolo V; Cianciulli A
Curr Pharm Des; 2010; 16(7):766-74. PubMed ID: 20388086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
